Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 May 2016

Drilon Alexander, Somwar Romel, Wagner Jacob P, Vellore Nadeem A, Eide Christopher A, Zabriskie Matthew S, Arcila Maria E, Hechtman Jaclyn F, Wang Lu, Smith Roger S, Kris Mark G, Riely Gregory J, Druker Brian J, O'Hare Thomas, Ladanyi Marc, Davare Monika A

Abstract excerpt

PURPOSE: Rearranged ROS1 is a crizotinib-sensitive oncogenic driver in lung cancer. The development of acquired resistance, however, poses a serious clinical challenge. Consequently, experimental and clinical validation of resistance mechanisms and potential second-line therapies is essential. EXPERIMENTAL DESIGN: We report the discovery of a novel, solvent-front ROS1(D2033N) mutation in a patient with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Anilides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigens, Differentiation, B-Lymphocyte

Share to Clinical Trials, Phase II as Topic

Share to Crizotinib

Share to Histocompatibility Antigens Class II

Share to Pyrazoles

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 26673800
DOI: 10.1158/1078-0432.CCR-15-2013
PMCID: PMC4867287

Genes

ROS1
CD74

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.PMID 26673800Read ↗

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitorsSemantic proximity Read ↗

Acquired resistance to crizotinib from a mutation in CD74-ROS1.Semantic proximity Read ↗

Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.Semantic proximity Read ↗

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.Semantic proximity Read ↗

Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central β-Sheet 6 [Cβ6] Mutation [L2086F]).Semantic proximity Read ↗

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.Semantic proximity Read ↗

Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.Semantic proximity Read ↗

SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors.Semantic proximity Read ↗

Molecular Changes Associated with Acquired Resistance to Crizotinib in <i>ROS1</i> -Rearranged Non–Small Cell Lung CancerSemantic proximity Read ↗

Crizotinib resistance conferred by BRAF V600E mutation in non-small cell lung cancer harboring an oncogenic ROS1 fusion.Semantic proximity Read ↗

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteinsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.